000			01773 a2200493 4500
005			20250516100225.0
264		0	_c20130114
008			201301s 0 0 eng d
022			_a1873-7064
024	7		_a10.1016/j.neuropharm.2012.06.012 _2doi
040			_aNLM _beng _cNLM
100	1		_aHuot, Philippe
245	0	0	_aL-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease. _h[electronic resource]
260			_bNeuropharmacology _cOct 2012
300			_a829-36 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAnimals
650	0	4	_aAntiparkinson Agents _xblood
650	0	4	_aBasal Ganglia _xmetabolism
650	0	4	_aBehavior, Animal _xdrug effects
650	0	4	_aBenserazide _xadministration & dosage
650	0	4	_aBiological Availability
650	0	4	_aCaudate Nucleus _xmetabolism
650	0	4	_aChromatography, High Pressure Liquid
650	0	4	_aDopamine Agents _xblood
650	0	4	_aDrug Combinations
650	0	4	_aDyskinesia, Drug-Induced _xetiology
650	0	4	_aFemale
650	0	4	_aHalf-Life
650	0	4	_aLevodopa _xadministration & dosage
650	0	4	_aMacaca fascicularis
650	0	4	_aMetabolic Clearance Rate
650	0	4	_aParkinsonian Disorders _xcerebrospinal fluid
650	0	4	_aSeverity of Illness Index
650	0	4	_aSpectrometry, Mass, Electrospray Ionization
650	0	4	_aTandem Mass Spectrometry
650	0	4	_aTissue Distribution
700	1		_aJohnston, Tom H
700	1		_aKoprich, James B
700	1		_aFox, Susan H
700	1		_aBrotchie, Jonathan M
773	0		_tNeuropharmacology _gvol. 63 _gno. 5 _gp. 829-36
856	4	0	_uhttps://doi.org/10.1016/j.neuropharm.2012.06.012 _zAvailable from publisher's website
999			_c21885361 _d21885361